Posts by Luke
FDA Vaping Policy Shows How Public Health Trust Gets Bypassed
A sudden FDA tobacco-policy shift shows how public-health agencies lose trust when process gets routed around the public.
Read MoreInhaled Insulin Approval Shows Innovation Still Runs Through the Paperwork Maze
The FDA’s pediatric approval of Afrezza is a real medical access story — and a reminder that innovation only matters if the system can deliver it safely, clearly, and affordably.
Read MoreThe Ebola Numbers Are a Public-Health Capacity Warning
WHO says Congo has 906 suspected Bundibugyo Ebola cases and 223 suspected deaths, a reminder that public health depends on capacity before politics.
Read MoreThe Ebola Outbreak Shows the Cost of Late Public-Health Detection
The Bundibugyo Ebola outbreak is a reminder that public-health capacity is not abstract until testing, surveillance, and trust arrive late.
Read More23andMe Shows Why Genetic Data Is Not Just Another Bankruptcy Asset
California’s lawsuit against 23andMe’s successor shows why genetic data cannot be treated like an ordinary hacked password or bankruptcy asset.
Read MoreCovid Vaccine Panel Vote Exposes the Data Gap Under Public Health
FDA advisers backed updating Covid shots for the XFG variant while warning that shrinking surveillance data is making annual vaccine decisions harder to trust.
Read MoreCVS’s Zepbound Reversal Shows the Real Drug-Pricing Machine
CVS Caremark is bringing Lilly Zepbound back as a preferred covered option, a reminder that drug access often turns on rebate negotiations rather than patient need alone.
Read MoreThe FDA’s Rare-Cancer Approval Shows the Trust Tradeoff in Fast Medicine
The FDA’s approval of AbbVie’s rare blood-cancer drug is a reminder that speed, risk and public trust now collide inside every accelerated medical pathway.
Read MoreCalifornia’s Trump-Fund Tax Fight Is About Who Gets Paid by Politics
California’s plan to tax Trump-fund payouts turns the January 6 compensation fight into a broader test of fiscal legitimacy and equal treatment.
Read MoreThe FDA Vape Shift Shows How Public Health Becomes a Lobbying Market
Reuters reports that the FDA’s new enforcement discretion could let hundreds of vapes and nicotine pouches reach the market without licenses, after tobacco-industry lobbying.
Read More